|
Accueil > Actualité
AstraZeneca: strong sales growth in Q1
(CercleFinance.com) - AstraZeneca reports total sales of $12,679m for Q1, up 17% y-o-y (or +19% at constant exchange rates).
Pre-tax earnings came to $2,800m, up 24% (+34% at constant exchange rates). The Anglo-Swedish laboratory reported adjusted quarterly EPS of $1.41, up 21% (+30% at constant exchange rates) on Q1 2023. Core EPS came to $2.06, up 7% (+13% at constant exchange rates). Management also highlighted the positive and "unprecedented" trial results obtained for Imfinzi and Tagrisso in lung cancer. It also looks forward to seeing the results of several other important trial projects throughout the year. Against this backdrop, AstraZeneca will announce a 7% increase in the annual dividend at its AGM. For 2024, AstraZeneca confirms its targets, with total sales and core EPS expected to rise by around 10% to 14%. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
15/05/2024 10:47
thyssenkruppatténue ses pertes au 2e trimestre 15/05/2024 10:42 Nestléinvestissement dans une usine Purina au Mexique 15/05/2024 10:25 Compassprévisions relevées, mais la marge déçoit un peu 15/05/2024 10:15 Burberryrepli de 41% du BPA lors de l'exercice 2023/24 15/05/2024 10:00 Renaultnouvelle collaboration avec WeRide dans l'autonomie 15/05/2024 09:55 ABN Amrohausse de 29% du bénéfice net au 1er trimestre Tous les articles sociétés |
